ELISA kits are commonly used to measure soluble biomarkers across a variety of research areas. ELISA kits for Human CrkL can be quantified in various samples, including plasma, serum, supernatant.
Invitrogen ELISA kits exist in two formats: Uncoated and Coated....ELISA kits are commonly used to measure soluble biomarkers across a variety of research areas. ELISA kits for Human CrkL can be quantified in various samples, including plasma, serum, supernatant.
Invitrogen ELISA kits exist in two formats: Uncoated and Coated. Uncoated ELISA kits...ELISA kits are commonly used to measure soluble biomarkers across a variety of research areas. ELISA kits for Human CrkL can be quantified in various samples, including plasma, serum, supernatant.
Invitrogen ELISA kits exist in two formats: Uncoated and Coated. Uncoated ELISA kits include all the necessary reagents to coat your own plates and run your assay with maximum flexibility. Coated ELISA kits...
ELISA kits are commonly used to measure soluble biomarkers across a variety of research areas. ELISA kits for Human CrkL can be quantified in various samples, including plasma, serum, supernatant.
Invitrogen ELISA kits exist in two formats: Uncoated and Coated. Uncoated ELISA kits include all the necessary reagents to coat your own plates and run your assay with maximum flexibility. Coated ELISA kits are ready-to-use and quality tested for sensitivity, specificity, precision and lot-to-lot consistency.
靶标信息
The CRKL gene encodes the CRK-like protein, an adaptor protein that plays a crucial role in intracellular signaling pathways related to cell proliferation, differentiation, and migration. CRKL contains SH2 and SH3 domains that facilitate interactions with other signaling molecules, influencing multiple pathways such as the MAPK, PI3K, and STAT pathways. It is involved in processes like cytoskeleton reorganization and immune cell signaling, with significant implications for development and cancer. CRKL is notably associated with Philadelphia chromosome-positive leukemias, where it interacts with the BCR-ABL fusion protein, contributing to leukemogenesis. Additionally, dysregulation of CRKL can affect cardiovascular development, leading to congenital heart defects. Research into CRKL focuses on understanding its role in signal transduction and its potential as a therapeutic target due to its involvement in oncogenic and developmental pathways.